Reprogramming the course of cancer

Technology

Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Pipeline

We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.

Management Team

We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us


At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

What they’re saying

In the Media


Catch up with our

Latest News


Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer

Genprex is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).

Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation on September 9, 2019 in New York City.

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.